The Priority Review

Tag

SonicForce

1 story

  1. Clinical trials

    Abbott reports strong 30-day outcomes in TECTONIC IVL study

    The TECTONIC CAD IVL IDE Study enrolled 335 patients and met its primary safety endpoint with a 30-day target lesion failure rate of 0.3%. The study also achieved a primary effectiveness endpoint with procedural success in 97% of patients.